MTAC - MedTech Acquisition Corporation
Chart Events
MACD
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 10.41 |
| Open | 10.41 |
| Bid | 10.41 x 1300 |
| Ask | 16.49 x 1000 |
| Day's Range | 10.41 - 10.41 |
| 52 Week Range | 9.80 - 10.68 |
| Volume | |
| Avg. Volume | 772 |
| Market Cap | 85.398M |
| Beta (5Y Monthly) | -0.03 |
| PE Ratio (TTM) | 208.20 |
| EPS (TTM) | 0.05 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- Business Wire
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases
DENVER & FORT LAUDERDALE, Fla., April 20, 2023--TriSalus Life Sciences® Inc., ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (Nasdaq: MTAC) ("MedTech" or "MTAC"), today announced new Phase 1 clinical data presented at the American Association for Cancer Research ("AACR") 2023 Annual Meeting taking place in Orlando, Florida, from April 14-19, 2023.
- Business Wire
TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business
DENVER & CHICAGO, February 21, 2023--TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (Nasdaq: MTAC) ("MedTech" or "MTAC"), today announced that James "Jim" Alecxih has joined the Company in the newly created role of President, Device Technology Business.
- GlobeNewswire
MedTech Acquisition Corporation Announces Adjournment of its Special Meeting in lieu of an Annual Meeting of Stockholders
The Company recommends all of its stockholders to vote FOR the Extension Amendment at the upcoming Special Meeting. New York, NY, Dec. 07, 2022 (GLOBE NEWSWIRE) -- MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or the “Company”) today announced that on December 7, 2022, it convened and then adjourned, without conducting other business, its special meeting of stockholders (the “Special Meeting”) in lieu of its 2022 Annual Meeting of Stockholders from December 7, 2022 to 11:00 a.m. East
American City Business JournalsColorado biotech company to go public via SPAC merger
The company develops technology for patients with liver and pancreatic cancers, which are uniquely difficult to treat.